CN109541226A - A kind of pepsinogen Cgene/II bigeminy check reagent box and preparation method thereof - Google Patents
A kind of pepsinogen Cgene/II bigeminy check reagent box and preparation method thereof Download PDFInfo
- Publication number
- CN109541226A CN109541226A CN201811329541.3A CN201811329541A CN109541226A CN 109541226 A CN109541226 A CN 109541226A CN 201811329541 A CN201811329541 A CN 201811329541A CN 109541226 A CN109541226 A CN 109541226A
- Authority
- CN
- China
- Prior art keywords
- magnetic
- bigeminy
- double antibody
- detection
- reagent box
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 44
- 108010047320 Pepsinogen A Proteins 0.000 title claims abstract description 29
- 206010015856 Extrasystoles Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 16
- 239000004005 microsphere Substances 0.000 claims abstract description 27
- 238000004140 cleaning Methods 0.000 claims abstract description 24
- 239000000872 buffer Substances 0.000 claims abstract description 21
- 239000003550 marker Substances 0.000 claims abstract description 19
- 238000004458 analytical method Methods 0.000 claims abstract description 15
- 101710198144 Endopolygalacturonase I Proteins 0.000 claims abstract description 11
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 claims abstract description 11
- 238000002372 labelling Methods 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 19
- 239000011324 bead Substances 0.000 claims description 18
- 238000005406 washing Methods 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 229910052693 Europium Inorganic materials 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 5
- 150000002602 lanthanoids Chemical class 0.000 claims description 5
- 229910052772 Samarium Inorganic materials 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- OEAHSWCPGQHDBE-UHFFFAOYSA-N 2-(4-aminophenyl)-2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound NC1=CC=C(C(N(CCN(CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)C=C1 OEAHSWCPGQHDBE-UHFFFAOYSA-N 0.000 claims description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 239000011368 organic material Substances 0.000 claims description 2
- 229960003330 pentetic acid Drugs 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- UXHQMSUJQLPRAW-UHFFFAOYSA-N benzene;isothiocyanic acid Chemical compound N=C=S.C1=CC=CC=C1 UXHQMSUJQLPRAW-UHFFFAOYSA-N 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 239000011806 microball Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 39
- 238000000034 method Methods 0.000 abstract description 17
- 230000008901 benefit Effects 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 238000002965 ELISA Methods 0.000 abstract description 4
- 230000035484 reaction time Effects 0.000 abstract description 4
- 238000007689 inspection Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000012224 working solution Substances 0.000 description 8
- 108090001072 Gastricsin Proteins 0.000 description 5
- 102000034255 Pepsinogen C Human genes 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108010092028 endopolygalacturonase II Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000011017 operating method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- INTFWQGUGQISAG-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]-2-phenylacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)C(C(O)=O)C1=CC=CC=C1 INTFWQGUGQISAG-UHFFFAOYSA-N 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of pepsinogen Cgene/II bigeminy check reagent boxes, are grouped as by following group: double antibody magnetic microballoon, I/II calibration object of PG, double antibody marker, analysis buffer, cleaning solution, enhancement solution and RFID card.This method is based on magnetic microsphere and combines with Timed-resolved fluoroimmunoassay, overcome the physical sorption reaction time of ELISA Plate longer, the slower drawback of testing result, the reaction time is greatly shortened, while also having that time resolution detection technique accuracy height, high sensitivity, high specificity, the range of linearity is wide, detection is stable and convenient advantage.The present invention advanced optimizes traditional two-step method detection, and detection only needs one-step method to detect, and result can be detected in 20 minutes.And it further, realizes two joint inspections of PG I/II using time resolution double labelling advantage, further shortens project result detection time.
Description
Technical field
The present invention relates to a kind of pepsinogen Cgene/II bigeminy check reagent boxes and preparation method thereof, and in particular to one kind is based on
Magnetic microsphere combines pepsinogen Cgene/II bigeminy check reagent box preparation method with Timed-resolved fluoroimmunoassay.
Background technique
Propepsin is the nonactive precursor of pepsin in gastric juice, can be divided into amphitypy in immunology: pepsinogen Cgene
(PG I) and Pepsinogen II (PG II), PG I are mainly secreted by the chief cell of fundus gland and mucus neck cell, and PG II remove by
Chief cell and mucus the neck cell secretion of fundus gland are outer, the mucus neck cell and duodenum of the pyloric gland of cardiac gland and antrum
Upper section secretion.During fundus gland mucosal atrophy, the chief cell of secretion PG I is reduced, pyloric gland cytosis, to cause PG
I/PG, II ratio reduces, horizontal by the detection of propepsin, especially I/PG of PG, II ratio and PG I, for diagnosing chronic
Atrophic gastritis, erosive gastritis, gastric ulcer, duodenal ulcer, atrophic gastritis and intestinal metaplasia have very high value.
1 part of serum sample detects two pepsinogen Cgene, Pepsinogen II projects simultaneously；Time-resolved fluoroimmunoassay
The multiple labeling advantage for analyzing (TRFIA), marks pepsinogen Cgene antibody, Pepsinogen II using two kinds of lanthanide series respectively
The mixed mark object of antibody, two kinds be coated with respectively pepsinogen Cgene antibody, Pepsinogen II antibody magnetic microsphere mixing
Liquid, then the double antibody sandwich method of double labelling can be formed in conjunction with two kinds of corresponding antibody in serum sample.Both the time is inherited
The advantages of Gao Min of resolved immuno fluorometric analytic approach, the wide line, high-accuracy property, while also the liquid phase with magnetic microsphere solution is special
Property, in conjunction with double labelling, further shorten the reaction time, detects result faster.It is sent out compared to chemiluminescence (CLIA), electrochemistry
Light (ECL) detection method, while reaching same performance detection, it may have inexpensive advantage.
Summary of the invention
Based on this, it is an object of the invention to overcome the associated disadvantages of the prior art, provide it is a kind of faster, more convenient and fast stomach
I/II bigeminy check reagent box of proproteinase and preparation method thereof.
To achieve the above object, the present invention adopts the following technical scheme that:
A kind of pepsinogen Cgene/II bigeminy check reagent box, is grouped as: double antibody magnetic microballoon, I/II school PG by following group
Quasi- product, double antibody marker, analysis buffer, concentration washing lotion (cleaning solution) and enhancement solution, RFID card.
Preferably, the magnetic microsphere is by micron-sized Fe2O3Or Fe3O4Magnetic particle and high-molecular organic material
Carry out compound, being formed has superparamagnetism, the micron-sized microballoon that can combine with immunising antigen or antibody, that is, is generally called
For " magnetic bead ".It is 0.1~5 μm that magnetic microsphere, which should be able to meet diameter, and magnetic microsphere can have various active function by surface modification
It can group, including but not limited to hydroxyl (- OH), amino (- NH2), carboxyl (- COOH).
Preferably, the double antibody magnetic microballoon is prepared using following steps:
By PG I, II antibody of PG respectively after 2~8 DEG C of superspeed refrigerated centrifuges are by buffer system replacement Treatment, with cleaning,
Magnetic microsphere mixing and constant-temperature incubation after activation, clean magnetic bead and abandon supernatant, then carried out with magnetic bead confining liquid after incubation
Closing, cleaning magnetic bead abandon supernatant again, and two kinds of high concentration antibody magnetic microspheres are saved 2~8 DEG C of refrigerators in liquid in magnetic bead
It is upright to save, then two kinds of magnetic beads are diluted to mix after working concentration, double antibody magnetic microballoon is made.
It is 10 μ g that every milligram of magnetic microsphere of EDC and Sulfo-NHS, which is preferably loaded quality, in the activation of the magnetic microsphere
~1000 μ g.Activation method includes but is not limited to EDC, Sulfo-NHS one such and two kinds.
Preferably, the antibody in the double antibody marker and lanthanide series are completed by intermediate chelating agent, group of the lanthanides
Element includes but is not limited to europium (EU), samarium (SM), and chelating agent includes but is not limited to isothiocyanic acid phenyl-EDTA, isothiocyanic acid benzene
Methyl D TTA, P- isothiocyanatobenzyl-DTTA, diethylene triamine pentaacetic acid aminophenyl-EDTA.
The present invention also provides a kind of methods using mentioned reagent box detection PG I/II, and described method includes following steps:
(1) double antibody marker is diluted to working solution with analysis buffer；
(2) working solution is diluted to by washing lotion is concentrated with purified water；
(3) double antibody magnetic microballoon is added in reaction cup；
(4) sample to be examined or calibration object are added in above-mentioned reaction cup；
(5) the double antibody marker working solution diluted in (1) is added in reaction cup；
(6) reaction cup is incubated at room temperature；
(7) magnetic microsphere after using the cleaning liquid in (2) to add magnetic in washing reaction cup；
(8) after washing, degaussing is added enhancement solution and is incubated for；
(9) after being incubated for, the fluorescent collecting for carrying out corresponding wavelength is detected and is analyzed.
Preferably, for the present invention in order to further reduce manual steps, self-produced SmartTRF grinds certainly in cooperation company
The relevant parameter of detection method, operating procedure are all copied to RFID card by complete series Immunofluorescence test equipment
In.In actual mechanical process, it is only necessary to RFID card is adapted to above-mentioned Immunofluorescence test equipment can be automatically finished it is above-mentioned
The operating procedure of experiment.RFID (Radio Frequency Identification) technology, also known as radio frequency identification, is one
The kind communication technology can be identified specific objective by radio signals and read and write related data, without identifying system and specific mesh
Mechanical or optical contact is established between mark.
The present invention also provides a kind of pepsinogen Cgene/II bigeminy check reagent box preparation methods, and the method includes as follows
Step:
(1) double antibody magnetic microballoon is prepared；
(2) double antibody marker is prepared；
(3) I/II calibration object of PG is prepared；
(4) analysis buffer, concentration washing lotion and enhancement solution are prepared；
(5) each component is dispensed respectively into corresponding storage container；
(6) RFID card duplicate copy；
(7) coding, labelling；
(8) it is assembled into finished product kit.
Compared with prior art, the beneficial effects of the invention are that:
This method is based on magnetic microsphere and combines with Timed-resolved fluoroimmunoassay, that is, overcomes the physical absorption of ELISA Plate anti-
Longer between seasonable, the slower drawback of testing result greatly shortens the reaction time, while it is accurate also to have time resolution detection technique
Property height, high sensitivity, high specificity, the range of linearity is wide, detection is stable and convenient advantage.The present invention is for traditional two-step method
Detection advanced optimizes, and detection only needs one-step method to detect, and result can be detected in 20 minutes.And it further, uses
Time resolution double labelling advantage realizes two joint inspections of PG I/II, further shortens project result detection time.In addition, due to
The fluid behaviour of magnetic microsphere buffer system is no longer limited by the frame limitation of traditional ELISA Plate, in arbitrary reaction cup and small
Detection can be completed in test tube, while volume size and the equipment cost of detecting instrument equipment can be reduced to meet two, three line cities
The full-automatic detection demand in city also can carry out big flux detection as ELISA Plate, the reflective detection of chemistry, meet a line city
Full-automatic detection demand.
Detailed description of the invention
Fig. 1 is to be used to store double antibody magnetic microballoon, double antibody marker, analysis using detection kit of the present invention
The schematic top plan view of the reagent strip of buffer, cleaning solution and enhancement solution.
Fig. 2 is to be used to store double antibody magnetic microballoon, double antibody marker, analysis using detection kit of the present invention
The schematic perspective view of the reagent strip of buffer, cleaning solution and enhancement solution.
Specific embodiment
The present invention is further illustrated with attached drawing with reference to embodiments, and it is special that technology of the invention is better described
Point, technical solution.Following embodiment does not cause any restrictions to the present invention.Magnetic microsphere is public from GE in following embodiment
Department；Europium label is purchased from Wallac company, Finland；Contrast agents box is that (chemiluminescence is micro- for Abbott Laboratories' pepsinogen Cgene assay kit
Particle immunodetection).
Embodiment 1
A kind of pepsinogen Cgene/II bigeminy check reagent box, the kit include: double antibody magnetic microballoon, I/II school PG
Quasi- product, I/II double antibody marker of PG, analysis buffer, concentration washing lotion and enhancement solution, RFID card.
The present invention also provides above-mentioned pepsinogen Cgene/II bigeminy check reagent box preparation methods, and the method includes as follows
Step:
(1) double antibody magnetic microballoon is prepared: by I/II antibody of PG respectively through 2~8 DEG C of superspeed refrigerated centrifuges by buffer body
It is to be mixed simultaneously constant-temperature incubation 1~3 hour, after incubation after replacement Treatment with 1 μm of carboxyl magnetic microsphere of diameter after cleaning, activation
Magnetic bead is cleaned using magnetic bead cleaning solution and abandons supernatant, is then closed with magnetic bead confining liquid, and cleaning magnetic bead abandons again
Supernatant, by I/II antibody magnetic microsphere of PG being coated in magnetic bead saves in liquid, 2~8 DEG C of refrigerators uprightly save.It again will coating
Good I/II antibody magnetic microsphere of PG is diluted to after working solution concentration with magnetic bead preservation liquid and is mixed and made into double antibody magnetic microballoon, is dispensed
At 10mL/ bottles.Preferably, magnetic microsphere and the coated mass ratio of I/II antibody of PG are divided into 30:1,20:1；Preferably, described
Displacement buffer and magnetic bead cleaning solution are the MES buffers of 0.05~0.5M PH, 5.8~PH 7.0；Preferably, magnetic microsphere
Activation in every milligram of magnetic microsphere of EDC and Sulfo-NHS be preferably loaded quality be 10 μ of μ g~1000 g；Preferably, magnetic
The Tris-HCl buffer that the confining liquid and preservation liquid of microballoon are 0.1~0.5M PH 7.0~8.5 containing 0.1%~8%BSA；
(2) prepare I/II double antibody marker of PG: it is 10000 ultra-filtration centrifuge tubes that I/II antibody of PG, which is placed in molecular cut off,
In, 10000rpm is centrifuged 7~10min, discards filtrate.Add 9.6 carbonate buffer solution 10000rpm of 0.05M PH centrifugation 7
~10min 2~3 times repeatedly, centrifuge tube filter membrane reversion 3000rpm is centrifuged 6min, collects 200 μ L solution being finally concentrated.And
By it respectively and in advance with the solvent DTTA-EU of carbonate buffer solution3、DTTA-SM3++Mixing, I/II antibody of PG and europium, samarium matter
Amount mixes 24 ± 2 hours than respectively 5:1,3:1,2~8 DEG C of oscillations.Label solution is buffered through 0.05M PH 7.8Tris-Hcl
The Sephadex of liquid balanceTMG-75 gel columnChromatographic purifying monitors in A280 and collects first peak.It will collect
I/II double antibody marker 0.2%BSA, 0.05M the PH 7.8Tris-Hcl buffer of PG arrived is diluted to the 1/ of optium concentration
It mixes, and is dispensed to 1.0mL/ bottles after 20 times.
(3) prepare I/II calibration object of PG: by from stomach lining II antigen of PGI, PG be diluted to respectively low, high two it is dense
Point is spent, and low, high concentration spot is mixed I/II calibration object of PG is made respectively.
(4) it prepares analysis buffer: containing Tween-20, Proclin300, EDTA, BSA, Tris-HCl buffer, dividing
It is filled to 30~40mL/ bottles.
(5) preparation concentration washing lotion: containing Tween-20, Proclin300, Tris-Hcl buffer, dispense to 30~
40mL/ bottles.
(6) enhancement solution is prepared: containing sodium acetate, β-NTA, TOPO, glacial acetic acid, dehydrated alcohol, TritonX-100, packing
To 30~40mL/ bottles.
(7) it prepares RFID card: blank RFID card is subjected to relative parameters setting by detection method in the present embodiment of the present invention；
(8) coding, labelling assemble kit.
The present invention also provides above-mentioned pepsinogen Cgene/II bigeminy check reagent box detection method, the method concrete operations
It is as follows:
(1) reagent prepares
1. kit restores in being placed at room temperature for room temperature；
2. I/II double antibody marker of PG is diluted to working solution concentration using analysis buffer, mix stand-by；
3. cleaning solution: purified water is added by 1:25 in concentration washing lotion and is diluted to work cleaning solution；
4. upright light rolling double antibody magnetic microballoon, mixes stand-by before experiment；
(2) experimental implementation
1. the double antibody magnetic microballoon for drawing 50 μ L mixing is added in reaction cup；
2. sample to be tested or I/II calibration object of PG, 100 μ L are added into each reaction cup；
3. the 100 μ L of double antibody marker working solution diluted is added into each reaction cup again；
4. room temperature blending incubation 20 minutes；
5. after being incubated for, being cleaned 4 times using cleaning solution；
6. 100 μ L of enhancement solution is added into each reaction cup, room temperature blending incubation 3 minutes；Fluorescence is completed in 30 minutes
It acquires and carries out data analysis.
In the present embodiment, actual laboratory operating procedures and relevant parameter are copied in matched RFID card in advance, real
It tests after operating process only needs to be ready to by reagent preparation process, RFID card is adapted to fully-automatic equipment can be completed from information
Read, be loaded onto the overall process of detection.
Embodiment 2
A kind of pepsinogen Cgene/II bigeminy check reagent box, it is essentially identical with detection kit described in embodiment 1, it is different
It is:
(1) pepsinogen Cgene/II bigeminy check reagent box component only includes: reagent strip, I/II calibration object of PG, RFID
Card.
(2) in the present embodiment, reagent strip is by double antibody magnetic microballoon, I/II double antibody mark of PG in the detection kit
It is formed after sealer in note object, analysis buffer, cleaning solution and enhancement solution, packing to the corresponding hole of reagent strip.Wherein cleaning solution is
Washing lotion is concentrated in embodiment 1 adds 25 times of purified water dilution to form；Remaining each component is in the same manner as in Example 1.
In the present embodiment, just as shown in Figure 1 and Figure 2, each hole bit function of reagent strip is described as follows in the detection kit:
Reagent strip is from left to right arranged successively, and title is followed successively by the 1st~13 hole.1st, 2 holes are instrument connection, the 3rd, 4
Hole be fluorescent marker hole, the 5th hole be analysis buffer hole, the 6th, 7 holes be cleaning fluid apertures, the 8th, 9 be Sample Dilution fluid apertures, the 12nd
To enhance fluid apertures, the 10th, 11,13 be preparation hole.1st and 2 holes are the reacting hole storing magnetic microsphere and being immunoreacted, most
It is 800 μ L that liquid volume can be stored greatly；3rd, 4 holes can be disassembled into from entire reagent strip and be independent component, convenient for glimmering
Signal object carries out packing storage.3rd, 4,5 holes can store maximum liquid volume be 400 μ L；6th, 7 holes can store maximum
Liquid volume is 3000 μ L；It is 400 μ L that 8th~12 hole, which can store maximum liquid volume,；13rd hole can store maximum liquid
Volume is 600 μ L.
In the present embodiment, the reagent strip in the detection kit is made after carrying out sealer as follows: by 300 μ L
I/II double antibody magnetic microballoon of PG, 50 μ L PG, I/II double antibody marker, 200 μ L analysis buffers, 3000 μ L cleaning solutions, 200
μ L enhancement solution is dispensed respectively to the 1st of reagent strip the, 3,5,6,12 holes, and the reagent strip is made after sealer.
The present invention also provides above-mentioned pepsinogen Cgene/II bigeminy check reagent box preparation methods, and examination is obtained in the above describe manner
After agent item, kit is constituted with I/II calibration object of PG, RFID card.In addition to each component packing mode and storage container are different
Outside, remaining is in the same manner as in Example 1.
The present invention also provides above-mentioned pepsinogen Cgene/II bigeminy check reagent box detection methods, it is only necessary to by mentioned reagent
Item is inserted into the reagent clamp bar slot of SmartTRF serial equipment after gently shaking mixing, and equipment reads RFID card relevant information can entirely certainly
It is dynamic to complete detection process.The related information parameters and detecting step of RFID card are in the same manner as in Example 1.
Embodiment 3
Pepsinogen Cgene of the present invention/II bigeminy check reagent box performance evaluation:
By the kit and detection method prepared in embodiment, detected with from Abbott Laboratories, hospital Architect i2000
The clinical sample of pepsinogen Cgene 240.The 2.5th percentiles of PG I is 63.8ng/mL in embodiment 1,2；PG II
95 percentiles are 22.5ng/mL.
Embodiment 1, embodiment 2 detect 240 Abbott Laboratories' pepsinogen Cgene, Pepsinogen II clinical samples, as a result such as
Under:
1 embodiment 1 of table, the comparison of 2 clinical samples
I/PG of PG, II ratio negative match-rate, positive coincidence rate are 100% in the embodiment of the present invention 1, embodiment 2.
What the concentration washing lotion (cleaning solution) referred in embodiment 1 is that the high concentration to be diluted to working solution is cleaned
Liquid；What cleaning solution referred in example 2 is the working solution for not needing any processing.
It should be understood that pepsinogen Cgene/II bigeminy check reagent box detection method and preparation method in embodiment 1
It is to be invented to meet big flux testing goal, instrument and equipment bulky and cost is relatively high, in order to further full
The detection demand in two, three line cities of foot, correspondingly, we have further made some detection methods on the basis of embodiment 1
And the modification on reagent box preparation method, as in embodiment 2.
It should be understood that difference of the present invention in example 2 with detection method and preparation method in embodiment 1 exists
In embodiment 2 is by double antibody magnetic microballoon, double antibody marker, analysis buffer, cleaning solution and the enhancing in embodiment 1
Liquid is dispensed into special reagent strip (as shown in Figure 1 and Figure 2) simultaneously, thus in embodiment 2 component of kit only have reagent strip,
RFID card, I/II calibration object of PG.Wherein it is consistent in RFID card, I/II calibration object of PG and embodiment 1.
It should be understood that the detection method of the present invention in example 2 is after reagent strip is inserted into detection device, to use simultaneously
Corresponding RFID card is adapted to equipment, and equipment full automatic working step is consistent with embodiment 1；
It should be understood that the preparation method of the detection kit of the present invention in example 2 it is different from embodiment 1
Become in, step (5) " calibration object is dispensed into calibration object bottle, remaining each component is dispensed respectively to the corresponding aperture of reagent strip,
Sealer coding immediately after having dispensed ".
Claims (6)
1. a kind of pepsinogen Cgene/II bigeminy check reagent box, it is characterised in that be grouped as by following group: double antibody magnetic microballoon,
I/II calibration object of PG, double antibody marker, analysis buffer, cleaning solution, enhancement solution and RFID card.
2. pepsinogen Cgene described in claim 1/II bigeminy check reagent box, which is characterized in that the magnetic microsphere be by
Micron-sized Fe2O3Or Fe3O4Magnetic particle and high-molecular organic material progress are compound, and being formed has superparamagnetism, Neng Gouyu
The micron-sized microballoon that immunising antigen or antibody combine.
3. pepsinogen Cgene described in claim 1/II bigeminy check reagent box, which is characterized in that the diameter of magnetic microsphere is
0.1~5 μm, magnetic microsphere has various active functional group, including but not limited to hydroxyl, amino or carboxylic by surface modification
Base.
4. pepsinogen Cgene described in claim 1/II bigeminy check reagent box, which is characterized in that the double antibody magnetic is micro-
Ball is prepared using following steps:
By PG I, II antibody of PG respectively after 2~8 DEG C of superspeed refrigerated centrifuges are by buffer system replacement Treatment, with cleaning, activation
Magnetic microsphere mixing and constant-temperature incubation afterwards, clean magnetic bead and abandon supernatant, then closed with magnetic bead confining liquid after incubation,
Cleaning magnetic bead abandons supernatant again, and two kinds of high concentration antibody magnetic microspheres are saved 2~8 DEG C of refrigerators in liquid in magnetic bead and are uprightly protected
It deposits, then two kinds of magnetic beads is diluted to mix after working concentration, double antibody magnetic microballoon is made.
5. pepsinogen Cgene described in claim 1/II bigeminy check reagent box, which is characterized in that the double antibody marker
In antibody and lanthanide series be to be completed by intermediate chelating agent, lanthanide series be europium or samarium, chelating agent be isothiocyanic acid benzene
Base-EDTA, isothiocyanic acid benzyl-DTTA, P- isothiocyanatobenzyl-DTTA or diethylene triamine pentaacetic acid aminophenyl-
EDTA。
6. pepsinogen Cgene described in claim 1/II bigeminy check reagent box preparation method, which is characterized in that including as follows
Step:
(1) double antibody magnetic microballoon is prepared；
(2) double antibody marker is prepared；
(3) I/II calibration object of PG is prepared；
(4) analysis buffer, concentration washing lotion and enhancement solution are prepared；
(5) each component is dispensed respectively into corresponding storage container；
(6) RFID card duplicate copy；
(7) coding, labelling；
(8) it is assembled into finished product kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811329541.3A CN109541226A (en) | 2018-11-09 | 2018-11-09 | A kind of pepsinogen Cgene/II bigeminy check reagent box and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811329541.3A CN109541226A (en) | 2018-11-09 | 2018-11-09 | A kind of pepsinogen Cgene/II bigeminy check reagent box and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109541226A true CN109541226A (en) | 2019-03-29 |
Family
ID=65846432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811329541.3A Pending CN109541226A (en) | 2018-11-09 | 2018-11-09 | A kind of pepsinogen Cgene/II bigeminy check reagent box and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109541226A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111398591A (en) * | 2020-04-03 | 2020-07-10 | 北京清分稳同科技有限公司 | Pepsinogen I and pepsinogen II combined detection kit and application thereof |
| CN112147328A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | An immunoassay kit based on pepsinogen PG I and its preparation method and detection method |
| CN112147333A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | Immunoassay kit based on pepsinogen PG II, and preparation method and detection method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8669849B2 (en) * | 2004-03-19 | 2014-03-11 | Applied Biosystems, Llc | Methods and systems for using RFID in biological field |
| CN107884567A (en) * | 2017-12-08 | 2018-04-06 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects Clenbuterol kit |
| CN108107220A (en) * | 2017-12-08 | 2018-06-01 | 广州源起健康科技有限公司 | A kind of fluorescence immunoassay magnetic particle quantitatively detects O-shaped foot-and-mouth disease antibody kit |
| CN108333357A (en) * | 2018-02-09 | 2018-07-27 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects CK-MB kits |
-
2018
- 2018-11-09 CN CN201811329541.3A patent/CN109541226A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8669849B2 (en) * | 2004-03-19 | 2014-03-11 | Applied Biosystems, Llc | Methods and systems for using RFID in biological field |
| CN107884567A (en) * | 2017-12-08 | 2018-04-06 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects Clenbuterol kit |
| CN108107220A (en) * | 2017-12-08 | 2018-06-01 | 广州源起健康科技有限公司 | A kind of fluorescence immunoassay magnetic particle quantitatively detects O-shaped foot-and-mouth disease antibody kit |
| CN108333357A (en) * | 2018-02-09 | 2018-07-27 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects CK-MB kits |
Non-Patent Citations (1)
| Title |
|---|
| 林颜玉等: "基于磁珠的胃蛋白酶原Ⅰ和Ⅱ双标记时间分辨荧光免疫分析试剂的研制", 《湖北大学学报( 自然科学版)》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111398591A (en) * | 2020-04-03 | 2020-07-10 | 北京清分稳同科技有限公司 | Pepsinogen I and pepsinogen II combined detection kit and application thereof |
| CN112147328A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | An immunoassay kit based on pepsinogen PG I and its preparation method and detection method |
| CN112147333A (en) * | 2020-08-31 | 2020-12-29 | 浙江博实生物科技有限公司 | Immunoassay kit based on pepsinogen PG II, and preparation method and detection method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109541227A (en) | A kind of detection pepsinogen Cgene kit and preparation method thereof | |
| US5358852A (en) | Use of calcium in immunoassay for measurement of C-reactive protein | |
| CN109541202A (en) | A kind of detection anti-HBs kit and preparation method thereof | |
| CN114814240B (en) | Beta amyloid protein detection kit | |
| CN111413501A (en) | Application of detection test strip in preparation of kit for detecting THSD7A antibody | |
| JPH01503405A (en) | Measuring analyte concentration using two labeled markers | |
| CN111024956A (en) | Time-resolved fluorescence immunochromatography kit for detecting PTX3 | |
| JPH07504498A (en) | Assays with improved dose-response curves | |
| EP3258266B1 (en) | Reagent kit used for detecting gastrin-17, and preparation method and application for reagent kit | |
| CN102187227B (en) | Methods for quantifying protein leakage from protein based affinity chromatography resins | |
| CN109541226A (en) | A kind of pepsinogen Cgene/II bigeminy check reagent box and preparation method thereof | |
| CN109164257A (en) | A kind of time-resolved fluoroimmunoassay detection method based on magnetic particle | |
| CN100439920C (en) | Detection of autoantibodies reactive with pancreatic islet cell antigen molecules and/or insulin | |
| CN109444415B (en) | Methoxyproterenol luminescent immunoassay kit | |
| KR101939891B1 (en) | Reagent for detecting target substance containing sugar chain, detection method, carrier used in detection of target substance containing sugar chain, and method for manufacturing said carrier | |
| CN109541228A (en) | A kind of detection Pepsinogen II kit and preparation method thereof | |
| DE19508772A1 (en) | Methods and connections for the detection of analytes by means of remanence measurement and their use | |
| CN109444417B (en) | Dopamine luminescence immunoassay kit | |
| CN107843733A (en) | The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of pregnancy-associated plasma protein | |
| Huang et al. | Receptor antibody time‐resolved A2 phospholipase bead immunochromatography and its application in idiopathic membranous nephropathy | |
| CN109541230A (en) | A kind of detection anti-HBc kit and preparation method thereof | |
| CN109541231A (en) | A kind of detection antibody of HCV kit and preparation method thereof | |
| CN101315364A (en) | Preparation method of immunochromatographic test strip for detecting cephalosporin antibiotics | |
| KR20010025027A (en) | Immunoassay reagents and immunoassay method | |
| CN109444416B (en) | Methoxy norepinephrine luminescent immunoassay kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190329 |